Back to top
more

BridgeBio Pharma (BBIO)

(Real Time Quote from BATS)

$24.86 USD

24.86
538,986

-0.60 (-2.36%)

Updated Apr 24, 2024 01:32 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (162 out of 252)

Industry: Medical - Generic Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Bayer (BAYRY) Banks on Pipeline Progress Amid Challenges

by Zacks Equity Research

Bayer (BAYRY) relies on pipeline candidate elinzanetant and key drugs, Nubeqa and Kerendia, to drive growth amid pipeline and regulatory setbacks.

Bayer (BAYRY) Acquires BridgeBio's Cardiovascular Drug

by Zacks Equity Research

Bayer (BAYRY) acquires exclusive marketing rights for cardiovascular drug acoramidis in Europe from BridgeBio for an upfront payment of $310 million.

BridgeBio Pharma (BBIO) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -1.05% and 74.53%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate BridgeBio Pharma (BBIO) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

BridgeBio Pharma (BBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BridgeBio Pharma (BBIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

BridgeBio Pharma (BBIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for XBI

CHMP Endorses BioMarin's (BMRN) Voxzogo for Use in Infants

by Zacks Equity Research

A final decision study on BioMarin's (BMRN) Voxzogo to treat children above four months with achondroplasia is expected before year's end.

Should You Invest in the SPDR S&P Biotech ETF (XBI)?

by Zacks Equity Research

Sector ETF report for XBI

Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for XBI

BridgeBio Pharma (BBIO) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -13.95% and 65.14%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Biotech Stock Roundup: BBIO, ARGX Soar on Study Results, APLS Down on Safety Issues

by Zacks Equity Research

Regulatory and key pipeline updates from BridgeBio (BBIO) and argenx (ARGX) are in focus in the biotech sector.

Here's Why You Should Add Alnylam (ALNY) Stock to Your Portfolio

by Zacks Equity Research

Alnylam's (ALNY) revenues continue to be driven by Amvuttra and Givlaari sales. Its existing collaboration agreement with Regeneron to develop RNAi-based candidates is progressing well.

BridgeBio (BBIO) Up as Heart Drug Meets Primary Goal in Study

by Zacks Equity Research

BridgeBio's (BBIO) shares surge on announcing positive data from a late-stage study evaluating acoramidis for patients with transthyretin amyloid cardiomyopathy.

Company News for Jul 18, 2023

by Zacks Equity Research

Companies In The News Are: F, TSLA, BBIO, PARA.

BridgeBio Pharma (BBIO) Moves 75.9% Higher: Will This Strength Last?

by Zacks Equity Research

BridgeBio Pharma (BBIO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

BridgeBio Pharma (BBIO) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -9.52% and 74.54%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Personalis (PSNL) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Personalis (PSNL) delivered earnings and revenue surprises of 1.61% and 8.72%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

BridgeBio Pharma (BBIO) Moves 9.7% Higher: Will This Strength Last?

by Zacks Equity Research

BridgeBio Pharma (BBIO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

BridgeBio Pharma (BBIO) Surges 77% YTD: Here's Why

by Zacks Equity Research

Shares of BridgeBio (BBIO) are up rising since the company announced positive data from a mid-stage study, which evaluated its experimental drug infigratinib in children with achondroplasia, a form of dwarfism.

Is BridgeBio Pharma (BBIO) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how BridgeBio Pharma (BBIO) and Bio-Rad Laboratories (BIO) have performed compared to their sector so far this year.

Biotech Stock Roundup: PTGX Gains on Study Data, BMRN Faces Setback & More

by Zacks Equity Research

Pipeline and regulatory updates from Protagonist (PTGX) and BioMarin (BMRN) are the key highlights from the biotech sector during the past week.

Company News for Mar 7, 2023

by Zacks Equity Research

Companies in The News Are: CIEN,BBIO,BA,SNAP

Does BridgeBio Pharma (BBIO) Have the Potential to Rally 67.36% as Wall Street Analysts Expect?

by Zacks Equity Research

The consensus price target hints at a 67.4% upside potential for BridgeBio Pharma (BBIO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

BridgeBio Pharma (BBIO) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -1.16% and 84.72%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Supernus Pharmaceuticals (SUPN) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Supernus (SUPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.